Physician profile
James Hall
NPI 1942678511
$2,054.18
in general payments reported to CMS, 2019-2025
20 companies · $37.34 in 2025
The $37.34 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $651 · 2023: $459 · 2024: $616 · 2025: $37.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.02 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $407.63 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $257.15 | 2022-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $217.97 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $122.95 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $80.96 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $49.20 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.06 | 2021-2022 | |
| Pfizer INC. | $43.28 | 2022-2023 | |
| Lundbeck LLC | $43.19 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $36.97 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Abiomed | $23.77 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $22.42 | 2023 | Rexulti |
| Pharmacosmos Therapeutics INC. | $19.61 | 2023 | Monoferric |
| Kowa Pharmaceuticals America, INC. | $19.53 | 2023 | Livalo, Seglentis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.87 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $18.73 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.77 | 2023 | Xifaxan |
| Abbott Laboratories | $12.91 | 2022 | |
| Evoke Pharma, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.